MENU

NRIX Stock Nurix Therapeutics (NRIX, $9.18) entered Downtrend as Momentum indicator drops below 0 level on Oct 14, 2025

A.I.dvisor
at Tickeron.com
Loading...
NRIX - Nurix Therapeutics
Momentum signal
Bearish Trend
Odds of DOWN Trend
Tickeron
Momentum signal
Price: $9.18
Daily change: -$0.54 (-5.56%)
Daily volume: 1.3M
Capitalization: $705.4M
Industry: Biotechnology
This indicator may be signaling that NRIX's price has further to drop, since it fell below its price logged 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options. A.I.dvisor backtested 84 similar cases where NRIX's Momentum Indicator fell below the 0 level, and of them led to a successful outcome. Odds of Success:

NRIX's RSI Oscillator recovers from overbought zone

The 10-day RSI Indicator for NRIX moved out of overbought territory on October 10, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 instances where the indicator moved out of the overbought zone. In of the 25 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 50 cases where NRIX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRIX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

NRIX broke above its upper Bollinger Band on October 09, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for NRIX entered a downward trend on September 29, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 15, 2025. You may want to consider a long position or call options on NRIX as a result. In of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for NRIX just turned positive on September 24, 2025. Looking at past instances where NRIX's MACD turned positive, the stock continued to rise in of 42 cases over the following month. The odds of a continued upward trend are .

NRIX moved above its 50-day moving average on October 15, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NRIX crossed bullishly above the 50-day moving average on October 10, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where NRIX advanced for three days, in of 260 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.033) is normal, around the industry mean (24.226). P/E Ratio (0.000) is within average values for comparable stocks, (54.529). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.181). Dividend Yield (0.000) settles around the average of (0.036) among similar stocks. P/S Ratio (9.699) is also within normal values, averaging (349.660).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NRIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
NRIX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. NRIX showed earnings on October 09, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which focuses on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
1700 Owens Street
Phone
+1 415 660-5320
Employees
284
Web
http://www.nurixtx.com